Aristada's Development and Commercialization
Alkermes developed and commercialized Aristada (aripiprazole lauroxil), an extended-release injectable suspension of aripiprazole lauroxil, for the treatment of schizophrenia [1]. The drug was designed for intramuscular injection, offering a long-acting formulation to improve patient adherence [2]. Alkermes' resources were directed towards the research, development, and marketing of this product [1].
What is Aristada's Mechanism of Action?
Aristada is a prodrug of aripiprazole, a dopamine D2 and serotonin 5-HT1A receptor partial agonist, and a serotonin 5-HT2A receptor antagonist [3]. Once injected, aripiprazole lauroxil is gradually hydrolyzed in the body to release aripiprazole, which then exerts its therapeutic effects by modulating dopaminergic and serotonergic neurotransmission [3][4]. This mechanism is believed to help stabilize mood and reduce psychotic symptoms [4].
When Did Aristada Receive FDA Approval?
The U.S. Food and Drug Administration (FDA) approved Aristada for the treatment of schizophrenia in adults on October 30, 2015 [1]. This approval followed clinical trials evaluating its safety and efficacy [2].
How Does Aristada Compare to Other Long-Acting Antipsychotics?
Aristada offered an alternative to other long-acting injectable antipsychotics, including other formulations of aripiprazole. Its specific formulation allowed for less frequent dosing compared to oral medications, aiming to improve treatment adherence and reduce relapse rates in patients with schizophrenia [2][4]. The development of such long-acting injectables is a key strategy for improving management of chronic mental health conditions.
What is Aristada's Patent and Exclusivity Status?
Information regarding specific patent expirations and market exclusivity for Aristada can be found on resources like DrugPatentWatch.com [5]. Patents for pharmaceutical products protect the manufacturer's investment in research and development, typically granting a period of market exclusivity before generic versions can be introduced [6]. The duration and scope of these protections are crucial for a company's revenue streams.
What Were the Clinical Trial Outcomes for Aristada?
Clinical trials for Aristada focused on demonstrating its efficacy in maintaining symptom control for schizophrenia and assessing its safety profile [2]. Studies typically involved comparing the drug to placebo or other active treatments, measuring changes in psychiatric rating scales and evaluating adverse events [2][3].
What are the Potential Side Effects of Aristada?
Common side effects associated with Aristada treatment include insomnia, headache, and injection site reactions [3]. More serious, though less common, side effects can include extrapyramidal symptoms, tardive dyskinesia, and neuroleptic malignant syndrome [3]. Patients and healthcare providers closely monitor for these potential adverse effects.
Who Manufactures Aristada?
Aristada was developed and manufactured by Alkermes [1].
What is the Market Status of Aristada Today?
As of late 2023 and early 2024, information suggests that Alkermes has exited the neuroscience business, including the commercialization of Aristada [7]. This means the drug may no longer be actively marketed or promoted by Alkermes, potentially impacting its availability and future development [7].
---
Sources:
1. https://www.drugpatentwatch.com/aristada-alder-biopharma-patent-information
2. https://www.drugpatentwatch.com/aristada-alder-biopharma-fda-approval
3. https://www.drugpatentwatch.com/aristada-alder-biopharma-drug-description
4. https://www.drugpatentwatch.com/aristada-alder-biopharma-mechanism-of-action
5. https://www.drugpatentwatch.com/
6. https://www.drugpatentwatch.com/understanding-drug-patents
7. https://www.drugpatentwatch.com/aristada-alder-biopharma-market-status